{"id":"91b52e10e67a","type":"article","url":"https://hartvaat.nl/2016/09/29/drug-eluting-of-bare-metal-stents-bij-coronairlijden-nejm-norstent-trial/","title":"Drug-eluting of bare-metal stents bij coronairlijden: NEJM NORSTENT-trial","title_en":"Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa1607991","source_url":"https://doi.org/10.1056/NEJMoa1607991","authors":["Kaare H Bønaa","Jan Mannsverk","Rune Wiseth","Lars Aaberge","Yngvar Myreng","Ottar Nygård","Dennis W Nilsen","Nils-Einar Kløw","Michael Uchto","Thor Trovik","Bjørn Bendz","Sindre Stavnes","Reidar Bjørnerheim","Alf-Inge Larsen","Morten Slette","Terje Steigen","Ole J Jakobsen","Øyvind Bleie","Eigil Fossum","Tove A Hanssen","Øystein Dahl-Eriksen","Inger Njølstad","Knut Rasmussen","Tom Wilsgaard","Jan E Nordrehaug"],"significance":9,"published":"2016-09-29","source_date":"2016-09-29","image":"","kennis":["https://hartvaat.nl/kennis/coronairlijden/pci-percutane-coronaire-interventie/"],"congress":"","summary_en":"The NORSTENT trial compared contemporary drug-eluting stents with bare-metal stents in a broad population of patients with coronary artery disease. No significant difference was found in the composite of death and MI at 6 years, though DES significantly reduced repeat revascularization, informing the ongoing debate about stent selection.","created":"2026-07-03T10:26:19Z","updated":"2026-07-03T13:25:39Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Landmark NEJM NORSTENT-trial die DES vergeleek met BMS bij een brede populatie coronairlijdenpatiënten. Onderzocht of het voordeel van DES ook geldt bij routinegebruik in de dagelijkse praktijk.","abstract_original":"BACKGROUND: Limited data are available on the long-term effects of contemporary drug-eluting stents versus contemporary bare-metal stents on rates of death, myocardial infarction, repeat revascularization, and stent thrombosis and on quality of life. METHODS: We randomly assigned 9013 patients who had stable or unstable coronary artery disease to undergo percutaneous coronary intervention (PCI) with the implantation of either contemporary drug-eluting stents or bare-metal stents. In the group receiving drug-eluting stents, 96% of the patients received either everolimus- or zotarolimus-eluting stents. The primary outcome was a composite of death from any cause and nonfatal spontaneous myocardial infarction after a median of 5 years of follow-up. Secondary outcomes included repeat revascularization, stent thrombosis, and quality of life. RESULTS: At 6 years, the rates of the primary outcome were 16.6% in the group receiving drug-eluting stents and 17.1% in the group receiving bare-metal stents (hazard ratio, 0.98; 95% confidence interval [CI], 0.88 to 1.09; P=0.66). There were no significant between-group differences in the components of the primary outcome. The 6-year rates of any repeat revascularization were 16.5% in the group receiving drug-eluting stents and 19.8% in the group receiving bare-metal stents (hazard ratio, 0.76; 95% CI, 0.69 to 0.85; P<0.001); the rates of definite stent thrombosis were 0.8% and 1.2%, respectively (P=0.0498). Quality-of-life measures did not differ significantly between the two groups. CONCLUSIONS: In patients undergoing PCI, there were no significant differences between those receiving drug-eluting stents and those receiving bare-metal stents in the composite outcome of death from any cause and nonfatal spontaneous myocardial infarction. Rates of repeat revascularization were lower in the group receiving drug-eluting stents. (Funded by the Norwegian Research Council and others; NORSTENT ClinicalTrials.gov number, NCT00811772 .)."}